A Phase III Randomised, Stratified, Parallel-Group, Multi-Centre, Comparative Study of ZD1839 (Iressa®) 250 Mg and 500 Mg Versus Methotrexate for Previously Treated Patients With Squamous Cell Carcinoma of the Head and Neck
Interventional
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Compare ZD1839 versus methotrexate in overall survival
AstraZeneca Iressa Medical Science Director, MD
Study Director
AstraZeneca
United States: Food and Drug Administration
1839IL/0704
NCT00206219
November 2003
September 2007
Name | Location |
---|---|
Research Site | Alabaster, Alabama |
Research Site | Mesa, Arizona |
Research Site | Anaheim, California |
Research Site | Boulder, Colorado |
Research Site | Danbury, Connecticut |
Research Site | Boca Raton, Florida |
Research Site | Albany, Georgia |
Research Site | Arlington Heights, Illinois |
Research Site | Ames, Iowa |
Research Site | Ashland, Kentucky |
Research Site | Baton Rouge, Louisiana |
Research Site | Bangor, Maine |
Research Site | Baltimore, Maryland |
Research Site | Battle Kreek, Michigan |
Research Site | Grand Island, Nebraska |
Research Site | Belleville, New Jersey |
Research Site | Albany, New York |
Research Site | Enid, Oklahoma |
Research Site | Allentown, Pennsylvania |
Research Site | Abington, Virginia |
Research Site | Auburn, Washington |
Research Site | Appleton, Wisconsin |